ArticleDiabetes research and clinical practice2026
Inverse association of insulin-like growth factor binding protein 1 with epicardial and intrathoracic adiposity in older adults: The Longenity study.
Article in Diabetes research and clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
aimsHigher serum insulin-like growth factor binding protein 1 (IGFBP-1) is associated with insulin sensitivity and reduced risk of obesity, diabetes, and atherosclerosis. Epicardial (EAT) and intrathoracic adipose tissue (IAT) are associated with increased atherosclerosis. Whether there is an inverse association of IGFBP-1 with EAT and IAT is unknown.
methodsWe measured EAT, IAT, and IGFBP-1 from n = 102 participants from the LonGenity parent study at the Albert Einstein Institute of Aging, Bronx NY, who were enrolled to investigate healthy aging in Ashkenazi Jewish offspring of parents with exceptional longevity (OPEL) vs usual survival (OPUS). Participants underwent non-contrast electrocardiogram-gated computed tomography (CT) for fat volume quantification. Multiple linear regression models for the cross-sectional association of IGFBP-1 with EAT and IAT were adjusted for demographic, clinical, and laboratory factors.
resultsHigher IGFBP-1 levels were statistically significantly associated with lower EAT and IAT, particularly in the OPEL. This inverse relationship remained significant after adjusting for age, body mass index, high-density lipoprotein cholesterol, and cardiometabolic factors. In contrast, among the OPUS, the point estimates for these associations were directionally similar but not statistically significant.
conclusionCirculating IGFBP-1 may be a novel biomarker for visceral adiposity and cardiometabolic risk stratification. Future studies should explore its role in cardiovascular aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.